Delving into the Latest Updates on DGPR1008 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DGPR1008

Target

PSMA

Action

inhibitors, enhancers

Mechanism

PSMA inhibitors(Prostate-specific membrane antigen inhibitors), Diagnostic imaging enhancers

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic Cancer

Inactive Indication-

Originator Organization

Daigepurui Biotechnology (Suzhou) Co., Ltd.

Active Organization

Daigepurui Biotechnology (Suzhou) Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Ⅰ期阶段：主要研究目的：评估DGPR1008在健康受试者中单次给药的安全性、耐受性和药代动力学特征。次要研究目的：根据安全性和药代动力学结果评估DGPR1008的最大耐受剂量（MTD）和临床Ⅱ期推荐剂量（RP2D）。 Ⅱ期阶段：主要研究目的：评估DGPR1008在患者中单次给药的安全性和药代动力学特征。次要研究目的：评估DGPR1008联合近红外荧光成像设备检测在患者手术中的成像的有效性。

[Translation]

Phase I stage: Main study objectives: To evaluate the safety, tolerability and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects. Secondary study objectives: To evaluate the maximum tolerated dose (MTD) and clinical phase II recommended dose (RP2D) of DGPR1008 based on safety and pharmacokinetic results. Phase II stage: Main study objectives: To evaluate the safety and pharmacokinetic characteristics of a single dose of DGPR1008 in patients. Secondary study objectives: To evaluate the effectiveness of imaging in patients during surgery using DGPR1008 combined with near-infrared fluorescence imaging equipment.

Start Date-

Sponsor / Collaborator

Daigepurui Biotechnology (Suzhou) Co., Ltd.

100 Clinical Results associated with DGPR1008

Login to view more data

100 Translational Medicine associated with DGPR1008

Login to view more data

100 Patents (Medical) associated with DGPR1008

Login to view more data

100 Deals associated with DGPR1008

Login to view more data